Orestis Pappas, MD
Interventional Cardiology · Erie, PANPI 1831499342
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 71.5% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2022 at $81,306 and has fallen 69.8% since, to $24,529 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,476 payments — averaging $175.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$185K
- Recor Medical Inc$13K
- Medtronic$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
- Abiomed$8K
- Johnson & Johnson$8K
- plus $28K from 38 others
Across 304 payments — averaging $960.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$252K
- Abbott$40K
What the payments were for
- Consulting fees$96,00037%
- Speaking & faculty fees$94,40036%
- Travel & lodging$17,8647%
- Food & beverage$50,75920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$195,538
- FLOWTRIEVER CATHETER, S$161,764
- Paradise Ultrasound Renal Denervation System$11,888
- LifeVest$7,831
- XARELTO$7,428
- Impella$3,466
- COREVALVE EVOLUT R$3,094
- RESOLUTE ONYX$2,589
- Indigo System$1,960
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,887
- WATCHMAN FLX$938
- SAPIEN 3 Ultra RESILIA$917
- CARDIOFORM Septal Occluder$682
- Repatha$574
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$501
- Pounce Venous Thrombectomy System$460
- PARADISE RENAL DENERVATION SYSTEM$434
- WATCHMAN Access System$393
- Pounce Thrombectomy System$338
- CoreValve Evolut$262
How this compares
$259,023 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 260 | $298,146 |
| EntrestoSacubitril/Valsartan | 166 | $199,837 |
| XareltoRivaroxaban | 146 | $172,028 |
| Repatha SureclickEvolocumab | 98 | $74,313 |
| BrilintaTicagrelor | 80 | $69,421 |
| JardianceEmpagliflozin | 41 | $57,029 |
| OzempicSemaglutide | 41 | $40,906 |
| FarxigaDapagliflozin Propanediol | 40 | $40,625 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $21,275 |
| Ranolazine ErRanolazine | 122 | $14,716 |
| Praluent PenAlirocumab | 11 | $10,338 |
| Metoprolol Succinate | 739 | $8,849 |
| Rosuvastatin Calcium | 494 | $7,200 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 365 | $4,006 |
| ClopidogrelClopidogrel Bisulfate | 403 | $3,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $298,146260 claims |
| NovartisEntresto | $547 | $199,837166 claims |
| Johnson & JohnsonXarelto | $7,721 | $172,028146 claims |
| AstraZenecaBrilinta, Farxiga | $446 | $110,046120 claims |
| Boehringer IngelheimJardiance | $267 | $57,02941 claims |
| Novo NordiskOzempic | $421 | $40,90641 claims |
| Esperion Therapeutics, Inc.Nexlizet | $547 | $21,27523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Erie
- Matthew BeckerErie$1M
- Nishant SethiScranton$1.3M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.